In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO 2026 and some of the key clinical datasets that could shape the next phase of oncology innovation.

Together, they discuss whether T-cell engagers can deliver transformative survival benefits in earlier lines of solid tumours with tarlatamab in DeLLphi-305; the promising science behind PD-1×VEGF combinations with Ivonescimab in HARMONi-GI1 and how we believe Merck & Co., Inc. are perceiving them; and Krascendo 1, a true head-to-head study that could help define a best-in-class KRAS G12C therapy and shape the future of the treatment landscape. Listen now to hear which studies the team are most excited about – and share insight into the ESMO data you will be watching most closely.

The IDEA and SAI teams will be in Madrid and look forward to connecting with colleagues to discuss the implications further.